Høfsten Dan Eik, Kelbæk Henning, Helqvist Steffen, Kløvgaard Lene, Holmvang Lene, Clemmensen Peter, Torp-Pedersen Christian, Tilsted Hans-Henrik, Bøtker Hans Erik, Jensen Lisette Okkels, Køber Lars, Engstrøm Thomas
The Heart Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
The Heart Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Am Heart J. 2015 May;169(5):613-21. doi: 10.1016/j.ahj.2015.02.004. Epub 2015 Feb 14.
In patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction, ischemic postconditioning has been shown to reduce infarct size, but the effect on clinical outcome has not been tested in a large randomized trial. In addition, deferring stent implantation in the infarct-related lesion 1 to 3 days after acute opening of the infarct-related artery could have protective effects, by reducing the risk of injury caused by distal embolization and microvascular obstruction. Finally, a considerable fraction of patients present with lesions in other coronary artery branches than the infarct-related artery. Whether a strategy of complete or partial revascularization of these patients should be preferred remains uncertain.
The DANAMI 3 trial program was designed to investigate 3 different randomized treatment strategies in patients with ST-segment elevation myocardial infarction: (1) ischemic postconditioning versus conventional treatment with a primary end point of death and hospitalization for heart failure; (2) deferring stent implantation in the infarct-related lesion versus conventional treatment with a primary end point of death, hospitalization for heart failure, reinfarction, and repeat revascularization; and (3) treatment of the culprit lesion only versus fractional flow reserve-guided complete revascularization in patients with multivessel disease, with a primary end point of death, reinfarction, and repeat revascularization.
The DANAMI 3 trial program will determine whether either of 2 approaches to reduce reperfusion injury and distal microvascular obstruction with postconditioning or deferred stent implantation will translate into improved clinical outcome and whether patients with multivessel disease undergoing primary percutaneous coronary intervention will benefit from a strategy of complete or partial revascularization.
在接受ST段抬高型心肌梗死直接经皮冠状动脉介入治疗的患者中,缺血后适应已被证明可减小梗死面积,但尚未在大型随机试验中检验其对临床结局的影响。此外,在梗死相关动脉急性开通后1至3天延迟在梗死相关病变处植入支架,可能具有保护作用,可降低远端栓塞和微血管阻塞所致损伤的风险。最后,相当一部分患者的病变存在于梗死相关动脉以外的其他冠状动脉分支中。对于这些患者是应优先采用完全血运重建还是部分血运重建策略仍不确定。
DANAMI 3试验计划旨在研究ST段抬高型心肌梗死患者的3种不同随机治疗策略:(1)缺血后适应与以死亡和因心力衰竭住院为主要终点的传统治疗;(2)延迟在梗死相关病变处植入支架与以死亡、因心力衰竭住院、再梗死和重复血运重建为主要终点的传统治疗;(3)仅治疗罪犯病变与在多支血管病变患者中采用血流储备分数引导的完全血运重建,以死亡、再梗死和重复血运重建为主要终点。
DANAMI 3试验计划将确定通过后适应或延迟支架植入来减少再灌注损伤和远端微血管阻塞的两种方法是否能转化为改善的临床结局,以及接受直接经皮冠状动脉介入治疗的多支血管病变患者是否将从完全或部分血运重建策略中获益。